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Abstract 24 
Objectives. Screening for Methicillin-resistant Staphylococcus aureus (MRSA) is 25 
part of many recommendations to control MRSA. Several rapid PCR tests are 26 
available commercially and updated versions are constantly released. We aimed to 27 
evaluate the performance of three consecutive versions (G3, Gen3 and NxG) of the 28 
XpertMRSA test. 29 
Methods. Routine samples for MRSA screening were simultaneously tested by 30 
culture and rapid PCR. The three versions of XpertMRSA were used successively 31 
and compared to culture. 32 
Results. A total of 3512, 2794 and 3288 samples were analyzed by culture and by 33 
the G3, Gen3 and NxG XpertMRSA versions, respectively. The rates of positive by 34 
culture in the three groups were 5.0%, 4.7% and 4.3%, respectively. The sensitivity 35 
improved over time (71.4 [95%CI, 64.0 – 77.9], 82.3 [95%CI, 74.4 – 88.2] and 84.3% 36 
[95%CI, 77.0-89.7], respectively), but non-significantly. The specificity (98.4 [95%CI, 37 
97.9 – 98.8], 96.8 [95%CI, 96.0 – 97.4] and 99.1 [95%CI, 98.7-99.4], respectively) 38 
and the positive likelihood ratios (45.7 [95%CI, 34.4 – 60.8], 25.6 [95%CI, 20.5 – 39 
32.0], 97.1 [95%CI, 66.3 – 142.4]) were significantly lower in the Gen3 version 40 
(p<0.00001). 41 
Conclusions. These significant differences in performance shows the importance to 42 
evaluate each new version of a commercial test. 43 
Introduction 44 
Methicillin-resistant Staphylococcus aureus (MRSA) remains a major cause of 45 
hospital-acquired infection with increasing morbidity, mortality and associated costs. 46 
Many countries have implemented recommendations and guidelines to prevent 47 
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MRSA spread (1, 2). Among these, screening at risk patients in order to manage 48 
positive carriers with additional control measures is advocated. Culture of screening 49 
samples remains the traditional and cheapest way to detect such microorganism, 50 
unfortunately with a turnaround time (TAT) to results of at least one or two days. With 51 
rapid commercial tests, a TAT of few hours can be achieved and this might be 52 
beneficial to the health care institution in several situations, such as (i) reduced time 53 
of pre-emptive isolation of the patient, (ii) an earlier control of the spread of the 54 
pathogen and  (iii) a better management of the patient's flow. For these reasons, the 55 
XpertMRSA screening test (Cepheid, Sunnyvale, CA) has been introduced in our 56 
hospital since 2009 and evaluated for a pool sample of nose, groin and throat swab 57 
(3). 58 
The XpertMRSA test is based on the amplification of the junction of the 59 
staphylococcal chromosomal cassette mec (SCCmec) and the chromosome. The 60 
earlier versions (up to G3) were designed based on the sequences of SCCmec I to 61 
IV. With the discovery of the last SCCmec XI and its specific mecC gene, it became a 62 
requisite to update the test to all SCCmec types. This was done in version Gen3 with 63 
the added amplification of the mecA or mecC genes, whereas version NxG benefited 64 
from a new design of all primers and an optimization to render the test more robust. 65 
In the present study, we prospectively evaluated the performance of three 66 
consecutive versions (G3, Gen3 and NxG) of the rapid PCR-based Xpert MRSA test, 67 
using culture methods and antimicrobial susceptibility testing as the reference 68 
standards for comparison. We also aimed to investigate discordances between 69 
culture and PCR test with a special focus on so-called "false positives". 70 
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Materiel and Methods 71 
Setting: The University Hospital of Lausanne is a 1’100-bed tertiary care hospital. 72 
Active surveillance cultures are part of its MRSA control program.  73 
Microbiological methods: Screening samples (nose, groin, and throat) were 74 
performed using the eSwab MRSA system (Copan, Italy) (4). This collecting device is 75 
composed of a screw-cap tube filled with 1 ml of Amies liquid and three swabs with 76 
flocked nylon fibber tips. The XpertMRSA test and culture were performed on all 77 
samples in parallel as previously described (3). Culture was considered as the gold 78 
standard and consisted in incubation of the sample into an enrichment broth followed 79 
by plating onto chromogenic agar which was incubated for 28 hours.  In case of 80 
invalid or error result with the XpertMRSA test, a second assay was performed. In the 81 
G3 version, Xpert MRSA yield positive results if only the SCCmec-chromosome 82 
junction is detected, whereas in the Gen3 and NxG versions both this junction and 83 
the mecA gene must be detected. Based on these results, the performances of the 84 
consecutive versions of the XpertMRSA were evaluated between March 2014 and 85 
March 2015 for the version G3, between March 2015 and February 2016 for Gen3, 86 
and between June 2016 and May 2017 for NxG. These performance indicators were 87 
the sensitivity, specificity, positive and negative predictive values (PV), the positive 88 
and negative likelihood ratio (LR). 89 
In cases of discordance between the results of rapid test and culture, additional 90 
analyses were performed prospectively. In case of false positive (rapid test positive, 91 
culture negative), the initial enrichment broth, which was kept at 4°C, was inoculated 92 
onto one S. aureus chromogenic plate (SAID, bioMérieux, Marcy l’Etoile, France) and 93 
one M-select plate (Bio-Rad, Marnes-la-Coquette, France). Growth of characteristic 94 
colonies on SAID and not on M-select was suspect of a S.aureus with a "SCCmec-95 
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like" element (5). Antimicrobial susceptibility testing and an XpertMRSA test (done 96 
directly on a colony) were performed to confirm or not this hypothesis. To investigate 97 
if the culture conditions were responsible for the false positive result, the initial broth 98 
was re-incubated for 24 hours and the stored sample was inoculated in a brain heart 99 
infusion (BHI) broth with 24h and 48h of incubation. All broths were inoculated onto 100 
M-select and SAID plates. In case of false negative, the XpertMRSA test was 101 
performed on one colony of the MRSA isolate which was kept frozen for further 102 
analysis. 103 
Patients’ data: Patient files of all discordance were retrospectively investigated for the 104 
search of risk factors for MRSA (MRSA history, infection with MRSA or MSSA, 105 
hospitalisation during the year before the discordant results, hospitalisation during 106 
the epidemic period 2008-2012 (6), transfer from an abroad hospital or from a 107 
nursing home, antibiotic treatment during the previous month, urinary or intra-108 
vascular catheter, wounds, surgery and dialysis). 109 
Statistical methods: The performance indicators were presented with their 95% 110 
confidence intervals according the Wilson score method (7, 8) proposal for positive 111 
and negative LR. These were calculated using the online calculator at 112 
http://vassarstats.net/clin1.html Comparison of proportion of false positives of the 3 113 
versions of XpertMRSA tests was based on the chi2 test. 114 
This study was approved by the local ethics commission (Commission Cantonale 115 
d'Ethique de la Recherche sur l'Etre Humain, Lausanne, Switzerland) under the 116 
number 2016-01045. Only patients giving a general authorisation to use their data 117 
and samples were included in the study. 118 
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Results 119 
Clinical performance characteristics 120 
A total of 9594 samples processed by rapid test and culture were included in the 121 
study. For 63 samples, the XpertMRSA results were invalid even after the second 122 
assay (Suppl. Materials, Table S1). Among the remaining 9531 samples, 445 were 123 
positive by culture and 514 by XpertMRSA (Suppl. Materials, Table S2). For each 124 
version of the test, the numbers of samples, periods of use, prevalence (percentage 125 
of culture positive), sensitivity, specificity, positive and negative predictive values and 126 
likelihood ratios (PLR and NLR) are shown in Table 1. The specificity and the PLR 127 
were significantly lower in the Gen3 version (p<0.00001 for Gen3 versus G3 or NxG). 128 
Sensitivity improved, but non-significantly, between the G3 and the NxG versions 129 
(Table 1). 130 
Discordances, false positives 131 
Among the 514 positive samples by PCR, 164 (32%) were culture-negative (Table 2). 132 
A significant reduction of discordance was observed in the last NxG generation of the 133 
test (G3 vs Gen3 : p< 0.0001; G3 vs NxG : p=0.011; Gen3 vs NxG p< 0.000001). 134 
The version Gen3 had the higher rate of false positive, most of them remaining 135 
negative after supplementary cultures. The positive likelihood ratio was the best 136 
performer for NxG;  the NxG test was nearly 100 times more likely to be positive 137 
when the culture was too (Table 1). 138 
The subculture of the enrichment broth onto a S. aureus chromogenic agar (SAID) 139 
allowed us to identify 63 MSSA isolates, which were phenotypically susceptible to 140 
methicillin and positive to the XpertMRSA test. This is highly suggestive for the 141 
presence of a SCCmec-like element (9). A significant decreased of such MSSA was 142 
observed between the version G3 or Gen3 and NxG (p= 0.107 and 0.0091). 143 
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Following additional cultures, a total of 18 MRSA were found. Five were obtained 144 
after a new subculture of the initial broth onto M-select agar, 2 by increasing the 145 
incubation of the enrichment broth to 48h, and 9 by inoculating the sample into a BHI 146 
broth. Two additional MRSA requiring specific condition were recovered (one needed 147 
an enriched CO2 atmosphere and the second grew only on the SAID agar). The last 148 
version NxG showed the lower rate of false positive for which additional cultures 149 
revealed the presence of MRSA (G3 vs NxG : p=0.014). 150 
The patient charts with false positive results and definitive negative culture were 151 
reviewed in order to find risk factors for MRSA infection/colonization (Suppl. 152 
Materials, Table S3). Among the 79 patients, 19/79 (24.2%) had at least one other 153 
sample positive for MRSA (5 developed an infection with MRSA) and 39/79 (49%) 154 
had an antibiotic treatment at the time of sampling or the month before. Most 155 
interesting, among the 12 false positive with the NxG version, 6 (50%) had at least 156 
one other sample positive for MRSA. 157 
Discordances, false negatives 158 
Among the 9017 negative samples by PCR, 95 were found positive by culture (Suppl. 159 
Materials, Table S2). Molecular typing of these isolates showed that 74 (78%)  160 
possessed a SCCmec type I, II, IV V and VI which are recognized by all the version 161 
of the XpertMRSA test (Suppl. Materials, Table S4). Moreover, the 22 isolates 162 
recovered during the use of version NxG were tested with the XpertMRSA assay and 163 
were all positive. For both Gen3 and NxG, negative likelihood ratio (LR-) were 164 
considered good (<0.2). 165 
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Discussion 166 
The aim of our study was to define the clinical performances of different versions of 167 
the rapid XpertMRSA test using pooled samples of nose, throat and groin. Significant 168 
differences were observed in the specificity and the positive predictive value between 169 
the different versions. The specificity was significantly better in the G3 (98.4%) and 170 
NxG (99.1%) versions than in the Gen3 version (96.8%). This is in agreement with a 171 
recent study showing the specificity of NxG to be better than Gen3 (10). Similarly, the 172 
PPV was also found to be better in the G3 version (70.6%) and NxG (81.4%) than in 173 
Gen3 (55.7%). A change in the incidence of MRSA in the population could explain 174 
these differences. However, this incidence remained stable over the period of the 175 
study (2014-2017) in our hospital and in the area (data from www.anresis.ch). The 176 
significant decrease of the specificity and the PPV in the version Gen3 was due to a 177 
higher number of false positives which could not be explained by further testing of the 178 
sample (Table 2). 179 
While not significant, the sensitivity and the NPV were both improved during the 180 
successive versions G3, Gen3 and NxG; whereas Jacquim et al. (10) showed the 181 
higher sensitivity with the Gen3 version.  182 
There are several reasons to explain discordances between results of XpertMRSA 183 
and culture. The first explanation is the presence of MSSA strain harboring a 184 
SCCmec-like element. The presence of such isolates in samples explained 38.4% of 185 
the false positives in our study and 25% in another study done in 2011 in France 186 
(11). We have previously shown that half of these isolates have the upstream 187 
sequence from the insertion site of the SCCmec highly similar to the SCC sequence 188 
(9). Others were due to isolates that have a SCC-like element (naturally without the 189 
mecA gene), and only a minority are former MRSA, which lost their mecA gene. The 190 
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amplification of the mecA or mecC gene was included in the last two versions of the 191 
XpertMRSA assay, Gen3 and NxG, in order to decipher such cases. Our results 192 
showed a significant improvement as only 13 (0.27 % of all XpertMRSA assay) such 193 
isolates were recorded in the NxG version compared to 24 (0.68 %) and 26 (0.93 %) 194 
in the G3 and Gen3 versions. We did not explain why the rate did not decrease with 195 
the version Gen3 which also include the mecA and mecC PCR. The addition of the 196 
mecA and mecC PCR in the assay did not resolved all cases. In our study, using the 197 
version NxG, we found the concomitant presence in the sample of MSSA with 198 
SCCmec-like and methicilin-resistant coagulase-negative staphylococci (data not 199 
shown), which led to a positive XpertMRSA result. 200 
The low bacterial charge of the sample and the culture condition might also explain 201 
these discordances. In our study, among the 85 false positive, 5 were found positive 202 
after a second culture and showed either a low number of colonies or the growth of 203 
other colonies, which may have hidden the MRSA. By increasing the incubation time 204 
of the enrichment broth, using a second broth (BHI) and a different agar plate, MRSA 205 
could be grown from 13 initially negative samples. Interestingly, we fortuitously 206 
isolated one MRSA that needed a CO2 enriched atmosphere to grow. The addition of 207 
such growth condition during the NxG version period did not revealed other similar 208 
strains (data not shown). Finally, discrepancies between rapid test and culture results 209 
could also be explained by the non-homogeneity of the sample despite the use of 210 
flocked swabs.  211 
The question of flagging patients as MRSA carrier based only on XpertMRSA results 212 
is raised. Considering the current version of XpertMRSA, 27/145 (18.6%) were false 213 
positive. Among them, 13 could be explained by the presence of MSSA with 214 
SCCmec-like element (which can be identified by routine culture of positive samples). 215 
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This leaves only 14 (9.7%) false positive among which two showed the presence of 216 
MRSA after additional culture, and for the remaining 12 samples, 6 had at least one 217 
other sample positive for MRSA (Table S3). Thus, if MSSA with SCCmec-like are 218 
identified by the laboratory, the probability that a positive XpertMRSA test reflect the 219 
past, present or future status of MRSA carrier of the patient is high. For these 220 
reasons, we advise to i) detect SCCmec-like MSSA and ii) flag the patient as MRSA 221 
carrier based on a positive Xpert MRSA result. 222 
False negative XpertMRSA results might be explained by inadequate or insufficient 223 
coverage of the diversity of SCCmec elements. The lower sensitivity (71.4 %) was 224 
observed with the G3 version, which was originally developed to target SCCmec I to 225 
IV. With the inclusion of all other SCCmec types known up to date, the sensitivity 226 
increased to over 80% in the Gen3 and NxG versions. The better coverage of the 227 
Nx3 XpertMRSA assay has already been assessed on a wide collection of diverse 228 
MRSA isolates by Becker et al. (12). Nevertheless, MRSA isolates recovered from all 229 
false negative samples using the NxG version were positive when tested with this 230 
assay. This highlights the sufficient coverage of the SCCmec type by the XpertMRSA 231 
assay in our epidemiological setting. The limit of detection (LOD) of XpertMRSA 232 
might also explain false negative specimens with a low charge of MRSA. An 233 
experimental assai showed that, following our laboratory protocols, at the limit of 234 
detection NxG XpertMRSA need an inoculum 100x higher than for culture to be 235 
positive (data not shown). Experimental errors could also be the reason of false 236 
negative. However, we did not retested these samples with XpertMRSA to 237 
investigate this hypothesis. The non homogeneity of the sample or the genetic 238 
diversity within SCCmec types (13) might be other hypothesis to explain these false 239 
negative. 240 
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One limitation of our study is that it was conducted in one center and consecutively. 241 
The advantage of a monocentric study is that standard laboratory procedures were 242 
used all over the study period. Due to logistic and financial resources, testing the 243 
three versions in parallel on the same samples was not feasible. However, we 244 
believe the possible effects of the consecutive study were limited due to a stable 245 
local epidemiology of MRSA (stable and low incidence, no recorded outbreaks, no 246 
predominant clone). 247 
In conclusion, significant differences in performance were observed between the 248 
different versions of the PCR Xpert® MRSA test. This was unexpected and shows 249 
the importance to evaluate new versions of commercial test. Fortunately, the worst 250 
version was used only for a year and was replaced by a version showing much better 251 
performances. 252 
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Table 2. Additional analysis on the 164 false positive samples (Xpert® MRSA 
positive, culture negative).  
 G3 Gen3 NxG p-values 
No of false positive 52 85 27 G3 vs Gen3 : p< 0.0001 
G3 vs NxG : p=0.01 
Gen3 vs NxG p< 0.000001 
MSSA with SCC-like element 24 26 13 G3 vs Gen3 : p=0.272 
G3 vs NxG : p= 0.107; 
Gen3 vs NxG : p= 0.0091 
MRSA found after 
supplementary cultures 
8 8 2 G3 vs Gen3 : p=0.85 
G3 vs NxG : p=0.014 
Gen3 vs NxG p=0.36 
Negatives 20 51 12 G3 vs Gen3 : p < 0.00001 
G3 vs NxG : p=0.218 
Gen3 vs NxG : p < 0.000001 
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Table 1. Data and performances of the different XpertMRSA versions compared to 
culture*. 
 G3 Gen3 NxG 
Period 04.2014-03.2015 03.2015-02.2016 06.2016-05.2017 
No analysis 3503 2776 3252 
Prevalence 
(95%CI)** 5.0% (4.3-5.8) 4.7% (4.0-5.5) 4.3% (3.7-5.1) 
Sensitivity 
% (95%CI) 71.4 (64.0 – 77.9) 82.3 (74.4 – 88.2) 84.3 (77.0-89.7) 
Specificity 
% (95%CI) 98.4 (97.9 – 98.8) 96.8 (96.0 – 97.4) 99.1 (98.7-99.4) 
PPV 
% (95%CI) 70.6 (63.2 – 77.1) 55.7 (48.4 – 62.8) 81.4 (73.9-87.2) 
NPV 
% (95%CI) 98.5 (98.0 – 98.9) 99.1 (98.6 – 99.4) 99.3 (98.9-99.5) 
PLR (95%CI) 45.7 (34.4 – 60.8) 25.6 (20.5 – 32.0) 97.1 (66.3 – 142.4) 
NLR (95%CI) 0.29 (0.23 – 0.37) 0.18 (0.11 – 0.26) 0.16 -0.11 – 0.23 
Accuracy (%) 97.1 95.5 97.4 
 
*. Based on results before additional analysis on discrepant results. 
**. Based on positives by culture. 
 
 
